Fabentech

Trending Articles

  1. MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for...
  2. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with...
  3. Shilpa Medicare signs commercial biologics manufacturing agreement with NXI Therapeutics The strategic partnership will see Shilpa provide development and manufacturing support for Swiss-based NXI Therapeutics, positioning it as a lifecycle partner for NXI's...
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a...
  5. Bora Group to acquire MacroGenics’ manufacturing operations and CDMO business The purchase will hand the Group a biologics drug substance manufacturing facility and a warehousing centre in Maryland, which Bora plans to use in cooperation with Tanvex...

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

Related Content

Research & Development

e-FabRIC consortium awarded €7.7m to develop broad-spectrum therapy against viruses with pandemic potential

The grant enables the development of novel treatments to combat Sarbecovirus epidemiological outbreaks
Subscribe now